THE STUDY OF RISK FACTOR AND STRATEGIES FOR PREVENTION OF RECURRENT ISCHEMIC STROKE:A COMPREHENSIVE SYSTEMATIC REVIEW
DOI:
https://doi.org/10.61841/w0n2j027Keywords:
Stroke, recurrent, SSA, DAPT, Vitamin DAbstract
Background: Studies show that the majority of strokes are caused by modifiable risk factors, such as high-fat diets, sleep apnea, diabetes, heart disorders, and other diseases. Recurrence rates are higher in sub-Saharan Africa (SSA), where strokes occur in the fourth or fifth decades of life. To reduce the risk of stroke recurrence and death, individuals who have survived their first stroke must undergo regular medical follow-up. Understanding the risk factors for stroke recurrence can help create plans and treatments to lessen the burden of strokes. Regular medical follow-up and understanding these risk factors can help create effective treatments and plans to reduce stroke recurrence.
Methods: This systematic review focused on full-text English literature published between 2014 and 2024, adhering to PRISMA 2020 principles. Without a DOI, editorials and review papers that were published in the same journal as the submission were not accepted. ScienceDirect, PubMed, and SagePub were among the many web resources used to compile the literature.
Result: Using reliable resources including Science Direct, SagePub, and PubMed, the study examined over 7,000 publications. Following the determination that seven publications warranted a further inquiry, a more thorough examination of the full corpus was conducted.
Conclusion: Risk factors such as hypertension, alcohol consumption, diabetes, female gender, non-adherence to treatment, and cardiac causes contribute to high stroke recurrence rates in sub-Saharan Africa. Treatment effectiveness varies among ethnic groups, with DAPT being effective in patients with ICAD. Statin-based therapies reduce recurrent stroke risk but increase hemorrhagic stroke risk. Vitamin D plays a crucial role in brain development.
References
Campbell, B. C. V., & Khatri, P. (2020). Stroke. The Lancet, 396(10244), 129–142. https://doi.org/10.1016/S0140-6736(20)31179-X
2. GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 19902019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2021 Oct;20(10):795820. doi: 10.1016/S1474-4422(21)00252-0. Epub 2021 Sep 3. PMID: 34487721; PMCID: PMC8443449..
3. Mbalinda, S., Kaddumukasa, M., Najjuma, J., Kaddumukasa, M., Nakibuuka, J., Burant, C., Moore, S., Blixen, C., Katabira, E., & Sajatovic, M. (2024). Stroke Recurrence Rate and Risk Factors Among Stroke Survivors in Sub-Saharan Africa: A Systematic Review. Neuropsychiatric Disease and Treatment, Volume 20(April), 783–791. https://doi.org/10.2147/ndt.s442507
4. O’Donnell, M. J., Chin, S. L., Rangarajan, S., Xavier, D., Liu, L., Zhang, H., Rao-Melacini, P., Zhang, X., Pais, P., Agapay, S., Lopez-Jaramillo, P., Damasceno, A., Langhorne, P., McQueen, M. J., Rosengren, A., Dehghan, M., Hankey, G. J., Dans, A. L., Elsayed, A., … Yusuf, S. (2016). Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. The Lancet, 388(10046), 761–775. https://doi.org/10.1016/S0140-6736(16)30506-2
5. Maredza, M., Bertram, M. Y., Gómez-Olivé, X. F., & Tollman, S. M. (2016). Burden of stroke attributable to selected lifestyle risk factors in rural South Africa Global health. BMC Public Health, 16(1). https://doi.org/10.1186/s12889-016-2805-7
6. Sandercock PA, Counsell C, Kane EJ. Anticoagulants for acute ischaemic stroke. Cochrane Database Syst Rev. 2015 Mar 12;2015(3):CD000024. doi: 10.1002/14651858.CD000024.pub4. Update in: Cochrane Database Syst Rev. 2021 Oct 22;10:CD000024. PMID: 25764172; PMCID: PMC7065522.
7. Sacco, R. L., Kasner, S. E., Broderick, J. P., Caplan, L. R., Connors, J. J., Culebras, A., Elkind, M. S. V., George, M. G., Hamdan, A. D., Higashida, R. T., Hoh, B. L., Janis, L. S., Kase, C. S., Kleindorfer, D. O., Lee, J. M., Moseley, M. E., Peterson, E. D., Turan, T. N., Valderrama, A. L., & Vinters, H. V. (2013). An updated definition of stroke for the 21st century: A statement for healthcare professionals from the American heart association/American stroke association. Stroke, 44(7), 2064–2089. https://doi.org/10.1161/STR.0b013e318296aeca
8. Li, G., Li, L., Adachi, J. D., Wang, R., Ye, Z., Liu, X., Thabane, L., & Lip, G. Y. H. (2022). Relationship between Serum 25-Hydroxyvitamin D Level and Risk of Recurrent Stroke. Nutrients, 14(9), 1–10. https://doi.org/10.3390/nu14091908
9. Flach, C., Muruet, W., Wolfe, C. D. A., Bhalla, A., & Douiri, A. (2020). Risk and Secondary Prevention of Stroke Recurrence: A Population-Base Cohort Study. Stroke, 51(8), 2435–2444. https://doi.org/10.1161/STROKEAHA.120.028992
10. Feigin, V. L., Forouzanfar, M. H., Krishnamurthi, R., Mensah, G. A., Bennett, D. A., Moran, A. E., Sacco,
R. L., Anderson, L., Donnell, M. O., Venketasubramanian, N., Barker-collo, S., Lawes, C. M. M., Wang, W., Shinohara, Y., Witt, E., & Ezzati, M. (2014). from the Global Burden of Disease Study 2010. 383(9913), 245– 254.
11. Adoukonou, T., Kossi, O., Fotso Mefo, P., Agbétou, M., Magne, J., Gbaguidi, G., Houinato, D., Preux, P. M., & Lacroix, P. (2021). Stroke case fatality in sub-Saharan Africa: Systematic review and meta-analysis. International Journal of Stroke, 16(8), 902–916. https://doi.org/10.1177/1747493021990945
12. Owolabi, M. O., Akarolo-Anthony, S., Akinyemi, R., Arnett, D., Gebregziabher, M., Jenkins, C., Tiwari, H.,
Arulogun, O., Akpalu, A., Sarfo, F. S., Obiako, R., Owolabi, L., Sagoe, K., Melikam, S., Adeoye, A. M., Lackland, D., & Ovbiagele, B. (2015). The burden of stroke in Africa: A glance at the present and a glimpse into the future. Cardiovascular Journal of Africa, 26(2), S27–S38. https://doi.org/10.5830/CVJA-2015-038
13. Akinyemi, R. O., Owolabi, M. O., Ihara, M., Damasceno, A., Ogunniyi, A., Dotchin, C., Paddick, S. M., Ogeng’o, J., Walker, R., & Kalaria, R. N. (2019). Stroke, cerebrovascular diseases and vascular cognitive impairment in Africa. Brain Research Bulletin, 145, 97–108. https://doi.org/10.1016/j.brainresbull.2018.05.018
14. Akinyemi, R. O., Ovbiagele, B., Adeniji, O. A., Sarfo, F. S., Abd-Allah, F., Adoukonou, T., Ogah, O. S., Naidoo, P., Damasceno, A., Walker, R. W., Ogunniyi, A., Kalaria, R. N., & Owolabi, M. O. (2021). Stroke in Africa: profile, progress, prospects and priorities. Nature Reviews Neurology, 17(10), 634–656. https://doi.org/10.1038/s41582-021-00542-4
15. Lin, B., Zhang, Z., Mei, Y., Wang, C., Xu, H., Liu, L., & Wang, W. (2021). Cumulative risk of stroke recurrence over the last 10 years: a systematic review and meta-analysis. Neurological Sciences, 42(1), 61–71. https://doi.org/10.1007/s10072-020-04797-5
16. Vergatti, A., Abate, V., Zarrella, A. F., Manganelli, F., Tozza, S., Iodice, R., De Filippo, G., D’Elia, L., Strazzullo, P., & Rendina, D. (2023). 25-Hydroxy-Vitamin D and Risk of Recurrent Stroke: A Dose Response Meta-Analysis. Nutrients, 15(3), 1–12. https://doi.org/10.3390/nu15030512
17. Kolmos, M., Christoffersen, L., & Kruuse, C. (2021). Recurrent Ischemic Stroke – A Systematic Review and Meta-Analysis. Journal of Stroke and Cerebrovascular Diseases, 30(8). https://doi.org/10.1016/j.jstrokecerebrovasdis.2021.105935
18. Shah, J., Liu, S., & Yu, W. (2022). Contemporary antiplatelet therapy for secondary stroke prevention: a narrative review of current literature and guidelines. Stroke and Vascular Neurology, 7(5), 406–414. https://doi.org/10.1136/svn-2021-001166
19. Grory, B. Mac, Yaghi, S., Cordonnier, C., Sposato, L. A., Romano, J. G., & Chaturvedi, S. (2022). Advances in recurrent stroke prevention: Focus on antithrombotic therapies. Circulation Research, 130(8), 1075–1094. https://doi.org/10.1161/CIRCRESAHA.121.319947
20. Lee, M., Cheng, C. Y., Wu, Y. L., Lee, J. Der, Hsu, C. Y., & Ovbiagele, B. (2022). Association Between Intensity of Low-Density Lipoprotein Cholesterol Reduction With Statin-Based Therapies and Secondary Stroke Prevention A Meta-analysis of Randomized Clinical Trials. JAMA Neurology, 79(4), 349–358. https://doi.org/10.1001/jamaneurol.2021.5578
21. Bangad, A., Abbasi, M., & de Havenon, A. (2023). Secondary Ischemic Stroke Prevention. Neurotherapeutics, 20(3), 721–731. https://doi.org/10.1007/s13311-023-01352-w
22. Mbonda, P.-C., Mafo, D., Doumbe, J., & Kuate, C. (2021). Recurrence of Strokes and Associated Factors at Laquintinie Hospital in Douala. Clinical Neurology and Neuroscience, 5(3), 46. https://doi.org/10.11648/j.cnn.20210503.12
23. Han, J., Mao, W., Ni, J., Wu, Y., Liu, J., Bai, L., Shi, M., Tu, J., Ning, X., & Wang, J. (2020). Rate and Determinants of Recurrence at 1 Year and 5 Years After Stroke in a Low-Income Population in Rural China. Frontiers in Neurology, 11(January), 1–9. https://doi.org/10.3389/fneur.2020.00002
24. Prabhakaran, S., Liebeskind, D. S., Cotsonis, G., Nizam, A., Feldmann, E., Sangha, R. S., Campo-Bustillo, I., & Romano, J. G. (2021). Predictors of Early Infarct Recurrence in Patients with Symptomatic Intracranial Atherosclerotic Disease. Stroke, 52(6), 1961–1966. https://doi.org/10.1161/STROKEAHA.120.032676
25. Wang, Y., Meng, X., Wang, A., Xie, X., Pan, Y., Johnston, S. C., Li, H., Bath, P. M., Dong, Q., Xu, A., Jing, J., Lin, J., Niu, S., Wang, Y., Zhao, X., Li, Z., Jiang, Y., Li, W., Liu, L., … Wang, B. (2021). Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA . New England Journal of Medicine, 385(27), 2520–2530. https://doi.org/10.1056/nejmoa2111749
26. Amarenco, P., Denison, H., Evans, S. R., Himmelmann, A., James, S., Knutsson, M., Ladenvall, P., Molina, C. A., Wang, Y., & Claiborne Johnston, S. (2020). Ticagrelor Added to Aspirin in Acute Nonsevere Ischemic Stroke or Transient Ischemic Attack of Atherosclerotic Origin. Stroke, 51(12), 3504–3513. https://doi.org/10.1161/STROKEAHA.120.032239
27. Liu, L., Wong, K. S. L., Leng, X., Pu, Y., Wang, Y., Jing, J., Zou, X., Pan, Y., Wang, A., Meng, X., Wang, C., Zhao, X., Soo, Y., Claiborne Johnston, S., & Wang, Y. (2015). Dual antiplatelet therapy in stroke and ICAS. Neurology, 85(13), 1154–1162. https://doi.org/10.1212/WNL.0000000000001972
28. Tan, C. H., Wu, A. G. R., Sia, C. H., Leow, A. S. T., Chan, B. P. L., Sharma, V. K., Yeo, L. L. L., & Tan, B. Y. Q. (2021). Cilostazol for secondary stroke prevention: Systematic review and meta-analysis. Stroke and Vascular Neurology, 6(3), 410–423. https://doi.org/10.1136/svn-2020-000737
29. Violi, F., Calvieri, C., Ferro, D., & Pignatelli, P. (2013). Statins as antithrombotic drugs. Circulation, 127(2), 251–257. https://doi.org/10.1161/CIRCULATIONAHA.112.145334
30. Kleindorfer, D. O., Towfighi, A., Chaturvedi, S., Cockroft, K. M., Gutierrez, J., Lombardi-Hill, D., Kamel, H., Kernan, W. N., Kittner, S. J., Leira, E. C., Lennon, O., Meschia, J. F., Nguyen, T. N., Pollak, P. M., Santangeli, P., Sharrief, A. Z., Smith, S. C., Turan, T. N., & Williams, L. S. (2021). 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American
Heart Association/American Stroke Association. In Stroke (Vol. 52, Issue 7). https://doi.org/10.1161/STR.0000000000000375
31. Muscogiuri, G., Annweiler, C., Duval, G., Karras, S., Tirabassi, G., Salvio, G., Balercia, G., Kimball, S., Kotsa, K., Mascitelli, L., Bhattoa, H. P., & Colao, A. (2017). Vitamin D and cardiovascular disease: From atherosclerosis to myocardial infarction and stroke. International Journal of Cardiology, 230, 577–584. https://doi.org/10.1016/j.ijcard.2016.12.053
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
